Telomir Pharmaceuticals, Inc. reported on October 8, 2025, that their compound Telomir-1 effectively kills aggressive triple-negative breast cancer cells in laboratory studies by disrupting their energy and iron balance, suggesting it may preferentially target cancer cells without harming healthy ones. This finding supports potential expanded studies into other cancer types as they prepare for an Investigational New Drug submission.